A nitroalkene derivative of salicylate, SANA, induces creatine-dependent thermogenesis and promotes weight loss

IF 20.8 1区 医学 Q1 ENDOCRINOLOGY & METABOLISM
Karina Cal, Alejandro Leyva, Jorge Rodríguez-Duarte, Santiago Ruiz, Leonardo Santos, Maria Pia Garat, Lucía Colella, Mariana Ingold, Andrés Benitez-Rosendo, Valentina Pérez-Torrado, Cecilia Vilaseca, German Galliussi, Lucía Ziegler, Thais R. Peclat, Mariana Bresque, Rachel M. Handy, Rachel King, Larissa Menezes dos Reis, João Manoel Alves, Camila Espasandín, Victoria de la Sovera, Peter Breining, Rosina Dapueto, Andrés Lopez, Katie L. Thompson, Caroline A. Lino, Julia V. França, Thayna S. Vieira, Ramandeep Rattan, Guillermo Agorrody, Evan DeVallance, Jacqueline Haag, Ethan Meadows, Sara E. Lewis, Gabriele Catarine Santana Barbosa, Leonardo Osbourne Lai de Souza, Marina Santos Chichierchio, Valeria Valez, Adrián Aicardo, Paola Contreras, Mikkel H. Vendelbo, Steen Jakobsen, Andrés Kamaid, Williams Porcal, Aldo Calliari, José Manuel Verdes, Jianhai Du, Yekai Wang, John M. Hollander, Thomas A. White, Rafael Radi, Guillermo Moyna, Celia Quijano, Robert O’Doherty, Pedro Moraes-Vieira, Shailendra Giri, Graham P. Holloway, William T. Festuccia, Luiz Osório Leiria, Roberta Leonardi, Marcelo A. Mori, Juliana Camacho-Pereira, Eric E. Kelley, Rosario Duran, Gloria V. López, Eduardo N. Chini, Carlos Batthyány, Carlos Escande
{"title":"A nitroalkene derivative of salicylate, SANA, induces creatine-dependent thermogenesis and promotes weight loss","authors":"Karina Cal, Alejandro Leyva, Jorge Rodríguez-Duarte, Santiago Ruiz, Leonardo Santos, Maria Pia Garat, Lucía Colella, Mariana Ingold, Andrés Benitez-Rosendo, Valentina Pérez-Torrado, Cecilia Vilaseca, German Galliussi, Lucía Ziegler, Thais R. Peclat, Mariana Bresque, Rachel M. Handy, Rachel King, Larissa Menezes dos Reis, João Manoel Alves, Camila Espasandín, Victoria de la Sovera, Peter Breining, Rosina Dapueto, Andrés Lopez, Katie L. Thompson, Caroline A. Lino, Julia V. França, Thayna S. Vieira, Ramandeep Rattan, Guillermo Agorrody, Evan DeVallance, Jacqueline Haag, Ethan Meadows, Sara E. Lewis, Gabriele Catarine Santana Barbosa, Leonardo Osbourne Lai de Souza, Marina Santos Chichierchio, Valeria Valez, Adrián Aicardo, Paola Contreras, Mikkel H. Vendelbo, Steen Jakobsen, Andrés Kamaid, Williams Porcal, Aldo Calliari, José Manuel Verdes, Jianhai Du, Yekai Wang, John M. Hollander, Thomas A. White, Rafael Radi, Guillermo Moyna, Celia Quijano, Robert O’Doherty, Pedro Moraes-Vieira, Shailendra Giri, Graham P. Holloway, William T. Festuccia, Luiz Osório Leiria, Roberta Leonardi, Marcelo A. Mori, Juliana Camacho-Pereira, Eric E. Kelley, Rosario Duran, Gloria V. López, Eduardo N. Chini, Carlos Batthyány, Carlos Escande","doi":"10.1038/s42255-025-01311-z","DOIUrl":null,"url":null,"abstract":"The emergence of glucagon-like peptide-1 agonists represents a notable advancement in the pharmacological treatment of obesity, yet complementary approaches are essential. Through phenotypic drug discovery, we developed promising nitroalkene-containing small molecules for obesity-related metabolic dysfunctions. Here, we present SANA, a nitroalkene derivative of salicylate, demonstrating notable efficacy in preclinical models of diet-induced obesity. SANA reduces liver steatosis and insulin resistance by enhancing mitochondrial respiration and increasing creatine-dependent energy expenditure in adipose tissue, functioning effectively in thermoneutral conditions and independently of uncoupling protein 1 and AMPK activity. Finally, we conducted a randomized, double-blind, placebo-controlled phase 1A/B clinical trial, which consisted of two parts, each with four arms: (A) single ascending doses (200–800 mg) in healthy lean volunteers; (B) multiple ascending doses (200–400 mg per day for 15 days) in healthy volunteers with overweight or obesity. The primary endpoint assessed safety and tolerability. Secondary and exploratory endpoints included pharmacokinetics, tolerability, body weight and metabolic markers. SANA shows good safety and tolerability, and demonstrates beneficial effects on body weight and glucose management within 2 weeks of treatment. Overall, SANA appears to be a first-in-class activator of creatine-dependent energy expenditure and thermogenesis, highlighting its potential as a therapeutic candidate for ‘diabesity’. Australian New Zealand Clinical Trials Registry registration: ACTRN12622001519741 . In this study, the authors describe SANA, a nitroalkene derivative of salicylate, as a potential activator of creatine-dependent energy expenditure and thermogenesis in adipose tissue. Preclinical and clinical data from this paper also suggest that SANA improves glucose homeostasis and promotes weight loss in mice and humans.","PeriodicalId":19038,"journal":{"name":"Nature metabolism","volume":"7 8","pages":"1550-1569"},"PeriodicalIF":20.8000,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.comhttps://www.nature.com/articles/s42255-025-01311-z.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature metabolism","FirstCategoryId":"3","ListUrlMain":"https://www.nature.com/articles/s42255-025-01311-z","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

The emergence of glucagon-like peptide-1 agonists represents a notable advancement in the pharmacological treatment of obesity, yet complementary approaches are essential. Through phenotypic drug discovery, we developed promising nitroalkene-containing small molecules for obesity-related metabolic dysfunctions. Here, we present SANA, a nitroalkene derivative of salicylate, demonstrating notable efficacy in preclinical models of diet-induced obesity. SANA reduces liver steatosis and insulin resistance by enhancing mitochondrial respiration and increasing creatine-dependent energy expenditure in adipose tissue, functioning effectively in thermoneutral conditions and independently of uncoupling protein 1 and AMPK activity. Finally, we conducted a randomized, double-blind, placebo-controlled phase 1A/B clinical trial, which consisted of two parts, each with four arms: (A) single ascending doses (200–800 mg) in healthy lean volunteers; (B) multiple ascending doses (200–400 mg per day for 15 days) in healthy volunteers with overweight or obesity. The primary endpoint assessed safety and tolerability. Secondary and exploratory endpoints included pharmacokinetics, tolerability, body weight and metabolic markers. SANA shows good safety and tolerability, and demonstrates beneficial effects on body weight and glucose management within 2 weeks of treatment. Overall, SANA appears to be a first-in-class activator of creatine-dependent energy expenditure and thermogenesis, highlighting its potential as a therapeutic candidate for ‘diabesity’. Australian New Zealand Clinical Trials Registry registration: ACTRN12622001519741 . In this study, the authors describe SANA, a nitroalkene derivative of salicylate, as a potential activator of creatine-dependent energy expenditure and thermogenesis in adipose tissue. Preclinical and clinical data from this paper also suggest that SANA improves glucose homeostasis and promotes weight loss in mice and humans.

Abstract Image

水杨酸盐的一种硝基衍生物SANA可诱导肌酸依赖性产热并促进体重减轻。
胰高血糖素样肽-1激动剂的出现代表了肥胖药物治疗的显著进步,但补充方法是必不可少的。通过表型药物发现,我们开发了含有硝基烯的小分子,用于治疗肥胖相关的代谢功能障碍。在这里,我们提出了SANA,一种水杨酸的硝基烯衍生物,在饮食诱导的肥胖的临床前模型中显示出显着的疗效。SANA通过增强线粒体呼吸和增加脂肪组织中肌酸依赖的能量消耗来减少肝脏脂肪变性和胰岛素抵抗,在热中性条件下有效发挥作用,独立于解偶联蛋白1和AMPK活性。最后,我们进行了一项随机、双盲、安慰剂对照的1A/B期临床试验,该试验由两部分组成,每部分有四组:(a)健康瘦志愿者单次递增剂量(200-800 mg);(B)超重或肥胖的健康志愿者多次递增剂量(每天200-400毫克,持续15天)。主要终点评估了安全性和耐受性。次要终点和探索性终点包括药代动力学、耐受性、体重和代谢指标。SANA显示出良好的安全性和耐受性,并在治疗2周内显示出对体重和血糖控制的有益效果。总的来说,SANA似乎是肌酸依赖性能量消耗和产热的一流激活剂,突出了其作为“糖尿病”治疗候选药物的潜力。澳大利亚新西兰临床试验注册:ACTRN12622001519741。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Nature metabolism
Nature metabolism ENDOCRINOLOGY & METABOLISM-
CiteScore
27.50
自引率
2.40%
发文量
170
期刊介绍: Nature Metabolism is a peer-reviewed scientific journal that covers a broad range of topics in metabolism research. It aims to advance the understanding of metabolic and homeostatic processes at a cellular and physiological level. The journal publishes research from various fields, including fundamental cell biology, basic biomedical and translational research, and integrative physiology. It focuses on how cellular metabolism affects cellular function, the physiology and homeostasis of organs and tissues, and the regulation of organismal energy homeostasis. It also investigates the molecular pathophysiology of metabolic diseases such as diabetes and obesity, as well as their treatment. Nature Metabolism follows the standards of other Nature-branded journals, with a dedicated team of professional editors, rigorous peer-review process, high standards of copy-editing and production, swift publication, and editorial independence. The journal has a high impact factor, has a certain influence in the international area, and is deeply concerned and cited by the majority of scholars.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信